RHRini Sasanti Handayani

Rini Sasanti Handayani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rini Sasanti Handayani has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chronic Disease Medicine Prices and Availability Under Indonesia’s National Health Social Security Agency (BPJS): A Cross-sectional Study from Jakarta and Yogyakarta

    by Selma Siahaan, Chairun Wiedyaningsih, Rini Sasanti Handayani, Endang Indriasih, Rachmalina Soerachman, Lucie Widowati, Ning Sulistiyowati

    This study aims to analyze the gap between financing mechanisms and the realities of the medicine market within the National Health Social Security Agency (BPJS) for chronic diseases in Indonesia. The article examines variations in procurement prices and medicine availability, and their implications for the financial sustainability of healthcare facilities and patient access. The cross-sectional study uses secondary data on procurement prices together with observations on the availability of chronic disease medicines in hospitals and pharmacies in Jakarta and Yogyakarta in 2024. The data were analyzed to identify patterns of variation and gaps between procurement prices and BPJS reimbursement levels. The results show price variation between facilities and regions, with medicine availability higher in pharmacies than in hospitals. BPJS reimbursement rates for some medicines do not cover procurement costs, which may cause financial losses for healthcare facilities and threaten supply sustainability. These findings point to weaknesses in BPJS medicine reimbursement and price-negotiation mechanisms. The recommendations call for pricing mechanisms that are more responsive to market dynamics, greater price transparency, and harmonized procurement policies to ensure sustainable access to chronic disease medicines. This Indonesian case study offers lessons for middle-income countries implementing national health insurance to achieve universal health coverage.

  • Open Access

    Pola Peresepan Anak dengan Infeksi Saluran Pernapasan Akut (ISPA) Non Pneumonia di Klinik

    by Rini Sasanti Handayani, Ida Diana Sari, Nita Prihartini, Yuyun Yuniar, Retno Gitawati

    Acute respiratory infection (ARI) is a common disease in the community. Riskesdas 2018 stated that ARI prevalence was 4.4% and the highest was in 1-4 years old children (8%). The capitation payment system in clinics collaborated with BPJS Kesehatan demands the physician to prescribe as effective and as efficient as possible. On the other hand, the capitation tariff obtained by clinics is considered as too low, thus constrains of the prescription leading to irrational prescribing is likely to occur. This study analyses further the prescribing pattern for ARI children in clinics and its rationality based on the difference in source of funding. A cross sectional research using retrospective method was conducted. Data were gathered from 409 medical records and or patients’ prescription of children between 1-12 years old and diagnosed as having non pneumonia ARI during 1st January to 30th November 2019. Result showed that non pneumonia ARI patients were mostly boys (54,3%) aged 1-5 years old (6.0%). The average number of items for BPJS patients was 3,45, the percentage of generic prescribing was twofold higher for BPJS group (63.94%), the percentage of essential medicine prescribing was 63.96% while the percentage of antibiotic use was lower (48.50%). Dosage propriety for BPJS patients was 70.80% which was slightly higher than non-BPJS group. Overall, the prescribing indicators and dosage properness for BPJS patients were better than non-BPJS patients.


  • Open Access

    Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

    by S. E. J. van de Berg, P. T. Pelzer, A. J. van der Land, E. Abdrakhmanova, A. Muhammad Ozi, M. Arias, S. Cook-Scalise, G. Dravniece, A. Gebhard, S. Juneja, et al.

    Background: BPaL, a 6 month oral regimen composed of bedaquiline, pretomanid, and linezolid for treating extensively drug-resistant tuberculosis (XDR-TB) is a potential alternative for at least 20 months of individualized treatment regimens (ITR). The ITR has low tolerability, treatment adherence, and success rates, and hence to limit patient burden, loss to follow-up and the emergence of resistance it is essential to implement new DR-TB regimens. The objective of this study was to assess the acceptability, feasibility, and likelihood of implementing BPaL in Indonesia, Kyrgyzstan, and Nigeria. Methods: We conducted a concurrent mixed-methods study among a cross-section of health care workers, programmatic and laboratory stakeholders between May 2018 and May 2019. We conducted semi-structured interviews and focus group discussions to assess perceptions on acceptability and feasibility of implementing BPaL. We determined the proportions of a recoded 3-point Likert scale (acceptable; neutral; unacceptable), as well as the overall likelihood of implementing BPaL (likely; neutral; unlikely) that participants graded per regimen, pre-defined aspect and country. We analysed the qualitative results using a deductive framework analysis. Results: In total 188 stakeholders participated in this study: 63 from Kyrgyzstan, 51 from Indonesia, and 74 from Nigeria The majority were health care workers (110). Overall, 88% (146/166) of the stakeholders would likely implement BPaL once available. Overall acceptability for BPaL was high, especially patient friendliness was often rated as acceptable (93%, 124/133). In contrast, patient friendliness of the ITR was rated as acceptable by 45%. Stakeholders appreciated that BPaL would reduce workload and financial burden on the health care system. However, several stakeholders expressed concerns regarding BPaL safety (monitoring), long-term efficacy, and national regulatory requirements regarding introduction of the regimen. Stakeholders stressed the importance of addressing current health systems constraints as well, especially in treatment and safety monitoring systems. Conclusions: Acceptability and feasibility of the BPaL regimen is high among TB stakeholders in Indonesia, Kyrgyzstan, and Nigeria. The majority is willing to start using BPaL as the standard of care for eligible patients despite country-specific health system constraints.


  • Open Access

    Challenges and social support provisions in the treatment of HIV infected children in Indonesia

    by Yuyun Yuniar, Rini Sasanti Handayani

    Latar belakang: Pengobatan pada anak yang terinfeksi HIV merupakan beban bagi para orang tua/pengasuh karena berbagai permasalahan menyangkut kesehatan mereka. Metode: Penelitian untuk mengeksplorasi pengalaman dan dukungan sosial pada pengobatan anak terinfeksi HIV dilakukan di 5 provinsi di Indonesia dengan prevalensi HIV tertinggi. Total sampel anak sebanyak 239 orang dari sejumlah 267 orang yang direncanakan. Data dikumpulkan dengan wawancara semi terstruktur dengan orang tua/pengasuhnya. Analisis dilakukan terhadap 16 anak berusia 2-14 tahun yang telah mendapatkan terapi obat antiretroviral. Hasil: Dari sejumlah 160 anak, sebanyak 62,5% anak mengkonsumsi 1-2 item obat dan 36,9% mengkonsumsi 3 5 item. Efek samping yang paling sering terjadi adalah kulit kemerahan, mual dan muntah. Kesulitan yang paling sering dihadapi adalah rasa bosan dan anak mempertanyakan minum obat. Orangtua/pengasuh berusaha melanjutkan pengobatan dengan mengingatkan jadwal minum obat, membujuk, memberikan penjelasan bahkan memaksa atau mengancam mereka untuk minum obat. Kesulitan tersebut makin bertambah seiring meningkatnya usia anak. Dukungan yang paling sering berasal dari orang tua dan keluarga besar seperti nenek atau paman, khususnya untuk anak yang sudah yatim. Kesimpulan: Pemahaman hambatan pengobatan pada anak terinfeksi HIV dapat membantu untuk menyediakan intervensi yang tepat untuk meningkatkan kepatuhan yang akan mendorong kesuksesan terapi mereka. Kata kunci: anak terinfeksi HIV, antiretroviral, dukungan social, pengobatan, kesulitan Abstract Background: The treatment of HIV infected children is a burden to their caregiver due to many existing problems related with their health. Methods: A research to explore the experience and social support on the treatment of HIV infected children was conducted in 5 provinces in Indonesia with highest prevalence of HIV. Total children sample was 239 out of previous 267 planned. Data was collected through semi structured interview with caregivers of the children. Analysis was conducted to 160 children aged 2-14 years old who were on antiretroviral therapy. Results: Among those 160 children, 62.5% took 1-2 items of medicines and 36.9% took 3-5 items. The most frequent adverse events were skin rash followed by nausea and vomiting. Boredom and questioning were the most frequent difficulties. The caregivers attempted to continue the treatment by reminding the children on schedule to take medicines, wheedling, explaining, forcing or even threatening them. The difficulties appeared more as the children grew older. The most frequent supports mainly came from parents, and extended family such as grandmother or uncle especially for orphaned children. Conclusion: Understanding obstacles in HIV infected children will help to do proper interventions to improve adherence that will lead to successful therapy. Keywords: HIV infected children, antiretroviral, social support, treatment, difficulties


  • Open Access

    ANALISIS SITUASI HAK KEKAYAAN INTELEKTUAL BIDANG KESEHATAN DI INDONESIA

    by Selma Siahaan, Basundari Sri Utami, Retno Gitawati, Rini Sasanti Handayani, Mukhlisul Faatih, Siti Isfandari

    The information about intellectual property rights (IPR) related to health products in Indonesia is limited. This manuscript aims to describes the situation of health innovative researches including their products (patented and copyrights) in the last 5 years (2009-2013). This is a cross-sectional exploratory qualitative research, followed by the identifi cation of data and information related to health IPR documents retrospectively from 2009 till 2013. In-depth interviews conducted on IPR managers in 5 (fi ve) government research institutions, Indonesia Institute of Science, Agency for the Assessment and Application of Technology and 7 (seven) universities in Java island. The results showed that the IPR policy is strong, because it is written in the Act, majority of institutions state that IPR is their main indicators, however, the priority of health innovative researches is low. Generally, patented products were not planned to be patented from the beginning. Not all institutions have IPR management structured and incubation unit for development and “scaling up” of researches results, so that, patented health products were potentially not to be commercialised. This shows that there is still a gap between policy and its implementation in terms of research innovation. Governments should actively promote and utilize the patented health products of Indonesia. Abstrak Informasi tentang Hak Kekayaan Intelektual (HKI) di Indonesia yang terkait dengan produk kesehatan masih sangat kurang. Tulisan ini bertujuan memaparkan situasi penelitian inovatif dan produk hasil penelitian kesehatan terkait HKI (paten dan hak cipta) dalam 5 tahun terakhir (2009-2013). Studi ini merupakan penelitian kualitatif eksplorasi potong lintang disertai identifi kasi data dan informasi pada dokumen HKI bidang kesehatan secara retrospektif dari tahun 2009 sd 2013. Wawancara mendalam dilakukan terhadap pengelola HKI di 5 (lima) lembaga litbang kementerian, Lembaga Ilmiah Pengetahuan Indonesia, Badan Pengkajian dan Penerapan Teknologi dan 7 (tujuh) universitas di pulau Jawa. Hasil penelitian menunjukkan bahwa dasar kebijakan HKI Indonesia telah kuat karena sudah dituangkan kedalam Undangundang, hampir semua institusi yang disurvei menjadikan HKI sebagai indikator utama, hanya penelitian yang berorientasi HKI kesehatan masih kurang diprioritaskan. Pada umumnya hasil penelitian yang dipatenkan tidak direncanakan sejak awal. Belum semua institusi memiliki unit pengelola HKI secara terstruktur dan unit inkubasi untuk pengembangan dan scaling up hasil penelitian agar dimanfaatkan masyarakat luas sehingga produk paten kesehatan berpotensi menjadi yang tidak bisa dikomersialisasikan. Hal ini menunjukkan bahwa terdapat gap antara kebijakan dan implementasinya dalam hal penelitian inovasi. Pemerintah perlu secara aktif membantu mempromosikan dan memanfaatkan hasil produk kesehatan yang telah memperoleh HKI.